EUVIMEDEUVIMED entdecken
Crossref

Therapeutic Drug Monitoring of Infliximab in Jordanian Patients

Nasir Idkaidek, Salim Hamadi, Luay Abu-Qatouseh, Hanaa Khalaf, Alaa Al-Hanahen, Abdo Mahli, Haya Tuffaha, Laith Alshoaibi, Mohammad Quta, Mohammad Ibrahim, Mahmoud Abualhaj, Aya Tarawneh und 10 weitere

Journal of Research in Pharmacy · 12.11.2026 · 30 (6) · 1498-1506

DOI: 10.12991/jrespharm.1908394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Research in Pharmacy, online erschienen am 12.11.2026. Verfasst von Nasir Idkaidek und 21 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Gefördert von: University of Petra.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Infliximab is a critical biologic therapy for severe inflammatory diseases, but its efficacy can be compromised by the development of anti-drug antibodies (ADAs). Therapeutic drug monitoring (TDM) is a recommended strategy to optimize treatment, but its implementation in Jordan has been limited. This study is the first to evaluate infliximab TDM in a Jordanian patient cohort.

Methods

Seventy-three Jordanian patients with inflammatory bowel disease (IBD) were recruited for this study. Trough levels of infliximab and ADAs were measured using enzyme-linked immunosorbent assay (ELISA). Clinical and demographic data, including Erythrocyte Sedimentation Rate (ESR) and smoking status, were collected and analyzed.

Results

A significant negative correlation was observed between infliximab trough levels and ADA levels (r = -0.69, p < 0.001). A notable 33.8% of patients developed high ADA titers (>100 ng/mL). ESR and smoking were significantly associated with lower infliximab levels and higher ADA levels. Other factors, such as hormones (Free T4, TSH), vitamins, and kidney and liver function tests, did not show significant correlations.

Conclusion

This study provides the first evidence from Jordan supporting the utility of TDM for infliximab. The high prevalence of ADAs and their correlation with negative clinical outcomes underscore the need for routine TDM to guide dosing strategies and improve patient outcomes in Jordan. The findings also highlight ESR and smoking as potential risk factors for treatment failure.

Förderung

  • University of Petra

Zitieren

APA

Idkaidek, N., Hamadi, S., Abu-Qatouseh, L., Khalaf, H., Al-Hanahen, A., Mahli, A., Tuffaha, H., Alshoaibi, L., Quta, M., Ibrahim, M., Abualhaj, M., Tarawneh, A., Zinati, A., Qudah, M., Alqashash, R., Jibril, M., Al-Armouti, M., Ayesh, A., Aljhani, A., …, & Alshawahin, Z. (2026). Therapeutic Drug Monitoring of Infliximab in Jordanian Patients. Journal of Research in Pharmacy, 30(6), 1498-1506. https://doi.org/10.12991/jrespharm.1908394

Vancouver

Idkaidek N, Hamadi S, Abu-Qatouseh L, Khalaf H, Al-Hanahen A, Mahli A, et al. Therapeutic Drug Monitoring of Infliximab in Jordanian Patients. Journal of Research in Pharmacy. 2026;30(6):1498-1506. doi:10.12991/jrespharm.1908394

BibTeX
@article{Idkaidek2026,
  author = {Idkaidek, Nasir and Hamadi, Salim and Abu-Qatouseh, Luay and Khalaf, Hanaa and Al-Hanahen, Alaa and Mahli, Abdo and Tuffaha, Haya and Alshoaibi, Laith and Quta, Mohammad and Ibrahim, Mohammad and Abualhaj, Mahmoud and Tarawneh, Aya and Zinati, Asmaa and Qudah, Moyad and Alqashash, Rola and Jibril, Motaz and Al-Armouti, Marwan and Ayesh, Ahmad and Aljhani, Aseel and Abusaif, Karmen and Matahen, Maisa and Alshawahin, Zaid},
  title = {Therapeutic Drug Monitoring of Infliximab in Jordanian Patients},
  journal = {Journal of Research in Pharmacy},
  year = {2026},
  volume = {30},
  number = {6},
  pages = {1498--1506},
  doi = {10.12991/jrespharm.1908394}
}
Kostenlos starten →